BioSpace News Archive

Lone Star Bio

Aravive to Participate In-Person at 34th Annual ROTH Conference

Aravive, Inc. announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, will participate in an in-person fireside chat at the 34th Annual ROTH Conference on Monday, March 14, 2022, at 8:30 am PT in HEALTHCARE VFC – Suite 2022 at The Ritz Carlton, Dana Point, California.

March 7, 2022
·
1 min read
Business

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

EyePoint Pharmaceuticals, Inc. today announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer.

March 7, 2022
·
5 min read
Drug Development

VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive preclinical data in an ex vivo skin model of vitiligo.

March 7, 2022
·
8 min read
Drug Development

Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis

Optinose today announced that the ReOpen1 clinical trial met both of its co-primary endpoints.

March 7, 2022
·
9 min read
Genetown

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for TIBSOVO.

March 7, 2022
·
16 min read
Business

Ionis calls for applications for Janice Wiesman Young Investigator Grant Program

Ionis Pharmaceuticals, Inc. announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program, which honors Janice Wiesman, M.D., a leading global expert on the neurological impact of amyloidosis.

March 7, 2022
·
2 min read
BioCapital

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Salubris Biotherapeutics, Inc. today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

March 7, 2022
·
5 min read
Business

Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

Scholar Rock today reported financial results for the full year ended December 31, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

March 7, 2022
·
11 min read
Business

Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

Centessa Pharmaceuticals plc today announced that Antoine Yver, MD, MSc, has been appointed Executive Vice President and Chairman of Development.

March 7, 2022
·
5 min read
Business

Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced its fourth quarter and full year 2021 financial results and highlighted recent corporate achievements.

March 7, 2022
·
9 min read